Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Auto-SCT in refractory celiac disease type II patients unresponsive to cladribine therapy.

Tack GJ, Wondergem MJ, Al-Toma A, Verbeek WH, Schmittel A, Machado MV, Perri F, Ossenkoppele GJ, Huijgens PC, Schreurs MW, Mulder CJ, Visser OJ.

Bone Marrow Transplant. 2011 Jun;46(6):840-6. doi: 10.1038/bmt.2010.199. Epub 2010 Sep 6.

PMID:
20818442
2.

Autologous hematopoietic stem cell transplantation in refractory celiac disease with aberrant T cells.

Al-toma A, Visser OJ, van Roessel HM, von Blomberg BM, Verbeek WH, Scholten PE, Ossenkoppele GJ, Huijgens PC, Mulder CJ.

Blood. 2007 Mar 1;109(5):2243-9. Epub 2006 Oct 26.

3.

Outpatient reduced-intensity allogeneic stem cell transplantation for patients with refractory or relapsed lymphomas compared with autologous stem cell transplantation using a simplified method.

Gutiérrez-Aguirre CH, Ruiz-Argüelles G, Cantú-Rodríguez OG, González-Llano O, Jaime-Pérez JC, García-Rodríguez F, López-Otero A, Herrera-Garza JL, Gómez-Almaguer D.

Ann Hematol. 2010 Oct;89(10):1045-52. doi: 10.1007/s00277-010-0986-1. Epub 2010 May 21.

PMID:
20490794
4.

Cladribine therapy in refractory celiac disease with aberrant T cells.

Al-Toma A, Goerres MS, Meijer JW, von Blomberg BM, Wahab PJ, Kerckhaert JA, Mulder CJ.

Clin Gastroenterol Hepatol. 2006 Nov;4(11):1322-7; quiz 1300. Epub 2006 Sep 18.

PMID:
16979946
5.

Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC).

Vigouroux S, Michallet M, Porcher R, Attal M, Ades L, Bernard M, Blaise D, Tabrizi R, Garban F, Cassuto JP, Chevalier P, Facon T, Ifrah N, Renaud M, Tilly H, Vernant JP, Kuentz M, Bourhis JH, Bordigoni P, Deconinck E, Lioure B, Socié G, Milpied N; French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC).

Haematologica. 2007 May;92(5):627-34.

6.

Allogenic hematopoietic stem-cell transplantation with reduced-intensity conditioning in patients with refractory and recurrent multiple myeloma: long-term follow-up.

Shimoni A, Hardan I, Ayuk F, Schilling G, Atanackovic D, Zeller W, Yerushalmi R, Zander AR, Kroger N, Nagler A.

Cancer. 2010 Aug 1;116(15):3621-30. doi: 10.1002/cncr.25228.

7.

Results of autologous stem cell transplant in multiple myeloma patients with renal failure.

Badros A, Barlogie B, Siegel E, Roberts J, Langmaid C, Zangari M, Desikan R, Shaver MJ, Fassas A, McConnell S, Muwalla F, Barri Y, Anaissie E, Munshi N, Tricot G.

Br J Haematol. 2001 Sep;114(4):822-9.

PMID:
11564069
8.

Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.

Hagemeister FB.

Cancer Chemother Pharmacol. 2002 May;49 Suppl 1:S13-20. Epub 2002 Apr 12. Review.

PMID:
12042984
9.

Allogeneic cell therapy for patients who relapse after autologous stem cell transplantation.

Porter DL, Luger SM, Duffy KM, Stadtmauer EA, Laport G, Schuster SJ, Orloff G, Tsai D, McDaid K, Kathakali A, Leonard DG, Antin JH.

Biol Blood Marrow Transplant. 2001;7(4):230-8.

PMID:
11349810
10.

Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells.

Corradini P, Dodero A, Zallio F, Caracciolo D, Casini M, Bregni M, Narni F, Patriarca F, Boccadoro M, Benedetti F, Rambaldi A, Gianni AM, Tarella C.

J Clin Oncol. 2004 Jun 1;22(11):2172-6.

PMID:
15169805
11.

Evaluation of Cladribine treatment in refractory celiac disease type II.

Tack GJ, Verbeek WH, Al-Toma A, Kuik DJ, Schreurs MW, Visser O, Mulder CJ.

World J Gastroenterol. 2011 Jan 28;17(4):506-13. doi: 10.3748/wjg.v17.i4.506.

12.

Prognostic value of comorbidity for auto-SCT eligibility and outcome in relapsed or refractory aggressive non-Hodgkin's lymphoma.

Plattel WJ, Kluin-Nelemans HC, de Bock GH, van Imhoff GW.

Bone Marrow Transplant. 2011 Jun;46(6):827-34. doi: 10.1038/bmt.2010.188. Epub 2010 Aug 23.

PMID:
20729926
13.

Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy.

Thomas DA, Kantarjian H, Smith TL, Koller C, Cortes J, O'Brien S, Giles FJ, Gajewski J, Pierce S, Keating MJ.

Cancer. 1999 Oct 1;86(7):1216-30.

PMID:
10506707
14.

Dexamethasone, carmustine, etoposide, cytarabine, and melphalan (dexa-BEAM) followed by high-dose chemotherapy and stem cell rescue--a highly effective regimen for patients with refractory or relapsed indolent lymphoma.

Josting A, Reiser M, Wickramanayake PD, Rueffer U, Draube A, Söhngen D, Tesch H, Wolf J, Diehl V, Engert A.

Leuk Lymphoma. 2000 Mar;37(1-2):115-23.

PMID:
10721775
15.

High-dose melphalan is an effective salvage therapy in acute myeloid leukaemia patients with refractory relapse and relapse after autologous stem cell transplantation.

Bug G, Atta J, Klein SA, Hertenstein B, Bergmann L, Boehrer S, Mousset S, Hoelzer D, Martin H.

Ann Hematol. 2005 Oct;84(11):748-54. Epub 2005 Jul 7.

PMID:
16001243
16.

Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation.

Sieniawski M, Angamuthu N, Boyd K, Chasty R, Davies J, Forsyth P, Jack F, Lyons S, Mounter P, Revell P, Proctor SJ, Lennard AL.

Blood. 2010 May 6;115(18):3664-70. doi: 10.1182/blood-2009-07-231324. Epub 2010 Mar 2. Erratum in: Blood. 2011 Feb 10;117(6):2077.

17.

Double reinforcement with fludarabine/high-dose cytarabine enhances the impact of autologous stem cell transplantation in acute myeloid leukemia patients.

Visani G, Lemoli RM, Isidori A, Piccaluga PP, Martinelli G, Malagola M, Gugliotta L, Bonini A, Bonifazi F, Motta MR, Rizzi S, Castellani S, Tura S.

Bone Marrow Transplant. 2001 Apr;27(8):829-35.

18.

Autologous stem cell transplantation for follicular lymphoma: no benefit for early transplant?

Seyfarth B, Kuse R, Sonnen R, Glass B, Schmitz N, Dreger P.

Ann Hematol. 2001 Jul;80(7):398-405.

PMID:
11529465
19.

Fotemustine plus etoposide, cytarabine and melphalan (FEAM) as a new conditioning regimen for lymphoma patients undergoing auto-SCT: a multicenter feasibility study.

Musso M, Scalone R, Marcacci G, Lanza F, Di Renzo N, Cascavilla N, Di Bartolomeo P, Crescimanno A, Perrone T, Pinto A.

Bone Marrow Transplant. 2010 Jul;45(7):1147-53. doi: 10.1038/bmt.2009.318. Epub 2009 Nov 9.

PMID:
19898504
20.

Phase II study of autologous stem cell transplant using busulfan-melphalan chemotherapy-only conditioning followed by interferon for relapsed poor prognosis follicular non-Hodgkin lymphoma.

Grigg AP, Stone J, Milner AD, Schwarer AP, Wolf M, Prince HM, Seymour J, Gill D, Ellis D, Bashford J; Australasian Leukaemia & Lymphoma Group.

Leuk Lymphoma. 2010 Apr;51(4):641-9. doi: 10.3109/10428191003611428.

PMID:
20218809

Supplemental Content

Support Center